Mesa Laboratories' Shares Up on Swing to Profit, Stabilizing Demand

Dow Jones

Feb 04

By Katherine Hamilton

Mesa Laboratories shares advanced after the company swung to a profit in the fiscal third quarter and said its end markets were stabilizing.

The stock rose 4.8% to $84.38 in late morning trading on Tuesday. Shares have gained 14% in the past three months.

The company, which provides quality-control tools, swung to a profit of $3.6 million, or 65 cents a share, from a loss of $1.7 million, or 31 cents a share, the year before.

Adjusted earnings were $3.07 a share, more than double the $1.40 that Wall Street was forecasting, according to FactSet.

The Lakewood, Colo., company also posted quarterly sales of $65.1 million, a 3.6% increase from the year-ago quarter. Analysts polled by FactSet expected $63.2 million in revenue.

Mesa said its end markets are stabilizing after a challenging macroeconomic environment plagued the start of its fiscal year.

Sales in its biopharmaceutical development business jumped about 18% to $14.4 million, driven by higher sales in immunoassays and peptides instruments.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

February 03, 2026 12:03 ET (17:03 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2608806534"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2608806534\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2608806534?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-04 01:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2608806534","market":"sg","top_or_hot":-1,"title":"Mesa Laboratories' Shares Up on Swing to Profit, Stabilizing Demand","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/MLAB\">Mesa Laboratories</a> shares advanced after the company swung to a profit in the fiscal third quarter and said its end markets were stabilizing. \n</p>\n<p>\n  The stock rose 4.8% to $84.38 in late morning trading on Tuesday. Shares have gained 14% in the past three months. \n</p>\n<p>\n  The company, which provides quality-control tools, swung to a profit of $3.6 million, or 65 cents a share, from a loss of $1.7 million, or 31 cents a share, the year before. \n</p>\n<p>\n  Adjusted earnings were $3.07 a share, more than double the $1.40 that Wall Street was forecasting, according to FactSet. \n</p>\n<p>\n  The Lakewood, Colo., company also posted quarterly sales of $65.1 million, a 3.6% increase from the year-ago quarter. Analysts polled by FactSet expected $63.2 million in revenue. \n</p>\n<p>\n  Mesa said its end markets are stabilizing after a challenging macroeconomic environment plagued the start of its fiscal year. \n</p>\n<p>\n  Sales in its biopharmaceutical development business jumped about 18% to $14.4 million, driven by higher sales in immunoassays and peptides instruments. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 03, 2026 12:03 ET (17:03 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Mesa Laboratories' Shares Up on Swing to Profit, Stabilizing Demand</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMesa Laboratories' Shares Up on Swing to Profit, Stabilizing Demand\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-02-04 01:03</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/MLAB\">Mesa Laboratories</a> shares advanced after the company swung to a profit in the fiscal third quarter and said its end markets were stabilizing. \n</p>\n<p>\n  The stock rose 4.8% to $84.38 in late morning trading on Tuesday. Shares have gained 14% in the past three months. \n</p>\n<p>\n  The company, which provides quality-control tools, swung to a profit of $3.6 million, or 65 cents a share, from a loss of $1.7 million, or 31 cents a share, the year before. \n</p>\n<p>\n  Adjusted earnings were $3.07 a share, more than double the $1.40 that Wall Street was forecasting, according to FactSet. \n</p>\n<p>\n  The Lakewood, Colo., company also posted quarterly sales of $65.1 million, a 3.6% increase from the year-ago quarter. Analysts polled by FactSet expected $63.2 million in revenue. \n</p>\n<p>\n  Mesa said its end markets are stabilizing after a challenging macroeconomic environment plagued the start of its fiscal year. \n</p>\n<p>\n  Sales in its biopharmaceutical development business jumped about 18% to $14.4 million, driven by higher sales in immunoassays and peptides instruments. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 03, 2026 12:03 ET (17:03 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4082","symbol_name":"医疗保健设备","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2608806534","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2608806534","pubTimestamp":1770138180,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Mesa Laboratories shares advanced after the company swung to a profit in the fiscal third quarter and said its end markets were stabilizing.The stock rose 4.8% to $84.38 in late morning trading on Tuesday. Shares have gained 14% in the past three months.The company, which provides quality-control tools, swung to a profit of $3.6 million, or 65 cents a share, from a loss of $1.7 million, or 31 cents a share, the year before.Adjusted earnings were $3.07 a share, more than double the $1.40 that Wall Street was forecasting, according to FactSet.The Lakewood, Colo., company also posted quarterly sales of $65.1 million, a 3.6% increase from the year-ago quarter. Analysts polled by FactSet expected $63.2 million in revenue.Mesa said its end markets are stabilizing after a challenging macroeconomic environment plagued the start of its fiscal year.Sales in its biopharmaceutical development business jumped about 18% to $14.4 million, driven by higher sales in immunoassays and peptides instrument","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4082":"医疗保健设备","BK4121":"生命科学工具和服务","MLAB":"Mesa Laboratories"},"translate_title":"梅萨实验室股价因扭亏为盈、需求稳定而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MLAB":1.5},"content_text":"By Katherine Hamilton \n\n\n \n\n\nMesa Laboratories shares advanced after the company swung to a profit in the fiscal third quarter and said its end markets were stabilizing. \n\n\n  The stock rose 4.8% to $84.38 in late morning trading on Tuesday. Shares have gained 14% in the past three months. \n\n\n  The company, which provides quality-control tools, swung to a profit of $3.6 million, or 65 cents a share, from a loss of $1.7 million, or 31 cents a share, the year before. \n\n\n  Adjusted earnings were $3.07 a share, more than double the $1.40 that Wall Street was forecasting, according to FactSet. \n\n\n  The Lakewood, Colo., company also posted quarterly sales of $65.1 million, a 3.6% increase from the year-ago quarter. Analysts polled by FactSet expected $63.2 million in revenue. \n\n\n  Mesa said its end markets are stabilizing after a challenging macroeconomic environment plagued the start of its fiscal year. \n\n\n  Sales in its biopharmaceutical development business jumped about 18% to $14.4 million, driven by higher sales in immunoassays and peptides instruments. \n\n\n \n\n\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 03, 2026 12:03 ET (17:03 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}